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ABSTRACT 
Background: Femoral central venous catheter (CVC) use is complicated by a 
high risk of proximal deep venous thrombosis (DVT). DVTs may result in 
potentially harmful pulmonary embolism (PE). Performing routine ultrasound after 
removal of femoral catheters to detect DVT and thus prevent pulmonary 
embolism (PE) has been suggested, but the potential cost-effectiveness of this 
strategy has not been examined. 
Objective: To evaluate the potential cost-effectiveness of routine unilateral 
duplex Doppler ultrasound versus no imaging study in averting PE-associated 
deaths associated with femoral CVCs among the critically ill. 
Design: Decision model. 
Data sources: Probabilities for clinical outcomes were obtained from meta-
analyses of clinical trials and literature syntheses of other prospective studies. 
Cost estimates were derived from average physician and Medicare 
reimbursements, institutional costs, and other sources. 
Target population: Mechanically ventilated 60-year old patients with femoral 
CVCs treated in a medical intensive care unit (ICU) for acute respiratory failure. 
Time horizon: Duration of hospitalization. 
Perspective: Health care payer. 
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Intervention: Unilateral duplex ultrasound examination of the proximal veins of 
the lower extremity performed after removal of a femoral CVC versus no 
ultrasound examination. 
"--
Outcome Measures: Costs, costs per PE-associated death and per PE averted, 
and incremental cost-effectiveness ratios. 
Results of Base-Case Analysis: A strategy of screening ultrasound cost 
$14,350 per PE death and $1 ,969 per PE averted compared with no imaging 
test. 
Results of Sensitivity Analyses: In one-way sensitivity analyses, the 
ultrasound strategy ranged from cost-saving to costs of $151,703 per PE death 
prevented after varying prevalence of CVC-associated DVT, probability of PE 
associated with DVT, sensitivity and specificity of ultrasound for DVT, and 
probability of eligibility to receive low-molecular weight heparin versus an Inferior 
vena cava {IVC) filter. 
Conclusions: A strategy of performing ultrasound after removing femoral CVCs 
appears to be a cost-effective modality in reducing both PE and PE deaths 
associated with CVCs among the critically ill. If further study confirms the benefits 
of preventing catheter-associated venous thromboembolic disease among the 
critically ill, then this study suggests that these improved outcomes come at 
acceptable costs for this population. 
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INTRODUCTION 
Almost half of the 31 million intensive care unit (leU) patients in the US receive 
central venous catheters (eves) annually 1• These catheters provide reliable 
intravascular access for life-sustaining medications and allow measurement of 
hemodynamic variables. Femoral vein placement of eves is popular and has 
advantages relative to subclavian and internal jugular vein placement including 
the comparative ease of insertion, lack of need for confirmatory imaging tests 
after insertion, and very low risk of potentially life-threatening acute complications 
such as pneumothorax. 
Despite their convenience, femoral eves are associated with significant 
complications such as catheter-related bloodstream infection and venous 
thrombosis . The incidence of ipsilateral proximal deep venous thrombosis (DVT) 
may be as great as 38% 2• Because more than 50% of proximal DVTs may result 
in pulmonary embolism (PE) 3·5 , the burden of catheter-associated venous 
thromboembolic disease is quite high among critically ill patients who require 
mechanical ventilation for respiratory failure and who have already limited 
cardiopulmonary reserve 6. 
Although cost-effective therapies exist for the treating DVT and DVT-associated 
complications such as PE 7, the best strategy for detecting eve-associated DVT 
and thus preventing eve-related pulmonary embolism PE is not clear. Physical 
exam alone is unreliable in this population 8, and patients often are unable to 
verbalize suggestive symptoms because of endotracheal intubation or sedation. 
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The reference standard, contrast venography, is rarely used because of its 
invasive nature and potential for nephrotoxicity 9• 
A more acceptable test to detect eve-related DVT may be lower extremity 
ultrasound, a test already used by most physicians managing leU patients as 
their primary DVT imaging modality. Ultrasound is relatively inexpensive, 
noninvasive, can be performed at the bedside without need for patient transport 
outside the leU, and is highly accurate for detecting symptomatic proximal DVT 
10
• However, it is less sensitive for detecting asymptomatic DVT 11 as is the 
typical case among leU patients. Therefore, it is uncertain if treatment based on 
ultrasound's lower positive predictive value would lead to excessive costly 
complications from anticoagulation or inferior vena cava filter placement in those 
falsely diagnosed with DVT. 
We developed a decision model to assess the potential cost-effectiveness of 
routine lower extremity Doppler ultrasound in preventing PE and PE-related 
death when performed after removal of femoral eves among critically ill patients 
requiring mechanical ventilation in a medical leu. We hypothesized that a 
strategy of screening ultrasound would result in acceptable costs relative to no 
ultrasound examination. Our patient population included those at high risk for 
DVT. These patients are the group most likely to experience poor outcomes from 
PE, and are therefore the most likely to be affected by such a screening strategy. 
We included sensitivity analyses to address the potential variability in baseline 
probabilities, outcomes incidences, as well as the accuracy of ultrasound testing 
within the target population. 
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METHODS 
We used a decision model to compare outcomes of ultrasound screening relative 
to no screening among the critically ill with femoral CVCs. Additionally, we 
incorporated two treatment strategies for positive tests on ultrasound, low-
molecular weight heparin (LMWH) and inferior vena cava interruption filters 
(IVCFs). The probabilities and costs used in the decision model are based on our 
judgement about the best estimates from the medical literature. For values that 
were not well-supported by the literature, we relied on the opinions of experts in 
critical care medicine and venous thromboembolic disease. 
Decision Model 
We performed a cost-effectiveness analysis by adopting a decision tree 
modelling approach and incorporating the recommendations of the Panel on 
Cost-Effectiveness in Health and Medicine in our research design and analysis 
12
. Figure 1 presents our full decision model in which two approaches to 
detection of catheter-associated DVT can be made: screening ultrasound after 
removal of femoral CVC versus no ultrasound. The ultrasound strategy used 
unilateral duplex Doppler examination of the proximal veins of the lower extremity 
catheterized by the femoral CVC. Patients with proximal DVT by ultrasound were 
treated with either low molecular weight heparin (LMWH) or an inferior vena cava 
(IVC) filter. The management of patients without proximal DVT by ultrasound or 
who did not receive screening ultrasound changed as clinically evident 
complications arose such as PE. In our model we assumed that outcomes are 
only those that clinicians could directly observe. By taking this approach, we 
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were only able to assess PEs detected clinically among those who did received 
no ultrasound. We also assumed that some DVTs and PEs among these 
severely ill, mechanically ventilated patients were clinically undetected and 
therefore were not associated with greater costs. 
Patients and Baseline Assumptions 
We analyzed treatment costs and important clinical outcomes relevant to a 60-
year old male patient with a femoral eve who received mechanical ventilation for 
acute respiratory failure. This demographic profile best represented the critically 
ill patients described in a recent international epidemiologic study of 5,183 
patients requiring mechanical ventilation, whose mean age was 59.2 and of 
whom 61.3% were male 13. Patients were assumed to receive mechanical 
ventilation for 7 days, stay in the leU for 8 days, remain on the hospital ward for 
an additional 7 days, and have a SAPS II score of 44 13. Although we did not take 
into account patients' underlying severity of illness in mortality calculations, we 
assumed the mortality rate would be approximately 33% during hospitalization 14• 
The base-case patient was assumed to receive DVT prophylaxis with sequential 
compression devices while in the leU. Femoral eves were assumed to have 
three lumens, were not heparin- or antibiotic-impregnated, and were left in place 
for at least 1 week. We defined DVT as a partial or complete occlusion of the 
proximal veins of the lower extremity on the ipsilateral side of the femoral eve. 
Time Horizon and Perspective 
The period of initial hospitalization was examined in our analysis. Therefore, we 
did not incorporate values for health states (utilities) to calculate quality-adjusted 
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life years (QAL Ys). We took the perspective of the health care payer in our cost 
analyses. 
Diagnostic and Treatment Alternatives 
In our model, a screening unilateral lower extremity ultrasound could be 
performed after removal of a femoral eve or not. If ultrasound was chosen, we 
assumed that all eligible patients found to have proximal DVT would be treated 
with LMWH because of its superior cost-effectiveness to unfractionated heparin 7 • 
In our analysis, enoxaparin given 1 mg/kg twice a day was used for LMWH 
calculations, assuming patients weighed 70kg. An IVeF was placed in those with 
contraindications to anticoagulation. If no DVT was detected by ultrasound, no 
therapy was given. We assumed that DVT was not clinically obvious in patients 8. 
Probability Estimates 
The probabilities of clinical events associated with femoral eve-related DVT 
used in our decision model are shown in Table 1. We have based these 
probabilities on review of the relevant literature including a MEDLINE search 
(1966 to April 2002) as well as a bibliographic search of retrieved articles' 
reference lists. Although data specific to critically ill medical ICU patients with 
catheter-associated DVT and PE are limited, we have included studies of the 
closest possible relevance to our target population and have utilized multiple 
sensitivity analyses to investigate the potential variability in variables with 
uncertain values. 
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Femoral eve-Associated DVT 
The prevalence of eve-associated DVT ranges from 9% to 38% among the 
critically ill and post-operative surgical patients 2· 15-22 . Our base-case probability 
of 21.5% for DVT is based on a large, randomized controlled trial comparing 
complications of femoral eves with subclavian eves in critically ill adults 2• We 
also performed a systematic review of femoral eve-associated venous 
thrombosis (Appendix 1). Sensitivity analyses included the lowest and highest 
rates from recent prospective studies of femoral eve-associated DVT 15-21 as 
well as a study based on autopsy results for eve-associated thrombi 22• 
Ultrasound 
The sensitivity (62%) and specificity (94%) of ultrasound were based on a meta-
analysis of sixteen clinical trials performed among asymptomatic hospitalized 
patients, most of whom were post-operative orthopedic patients in 1eus 11 • We 
examined ranges for both sensitivity (15-75%) and specificity (75-98%) in 
sensitivity analyses based on the reported confidence intervals of this meta-
analysis. Such post-operative patients are likely to fairly approximate the 
thromboembolic risk and logistic imaging difficulties (patient positioning, edema, 
need for bedside testing) of medical leu patients. 
Pulmonary Embolism 
The 30% probability of PE resulting from DVT was derived from pooled rates 
reported in three prospective studies 3· 5· 23 as well as from one large, randomized 
trial of leU patients 2 that examined PE incidence among hospitalized patients. 
Our sensitivity analyses reflect the likelihood that the critically ill may experience 
a higher incidence than other less severely ill hospitalized patients because of 
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their many risk factors for thromboembolic disease as well as the difficulty in 
diagnosing this condition within such a group of sedated, mechanically ventilated 
patients. We based the probability of PE while being treated with LMWH (1.9%) 
on results of a meta-analysis comparing LMWH with unfractionated heparin for 
the treatment of DVT 24• Sensitivity analyses include data from a large 
randomized trial comparing IVC filters versus LMWH for prevention of PE among 
those with DVTs 25• A mortality rate of 30% from untreated PE is based results of 
a systematic review 26 and sensitivity analyses include the ranges of individual 
studies' reported mortality rates (18%-38%). Finally, both the probability of PE 
and death from PE after IVC filter placement was based on results of a 400-
patient randomized trial of IVC filters versus low-molecular weight hepain for 
prevention of PE in those with proximal deep vein thrombosis 25• This is the only 
randomized trial evaluating outcomes of IVC filter placement to our knowledge. 
Treatment Eligibility 
Patients found to have proximal femoral vein DVT by ultrasound were treated 
with LMWH if they had no contraindications to anticoagulation. Those who could 
not receive LMWH for any reason received an IVC filter. We estimated that 
approximately two-thirds of patients would be eligible to receive LMWH based on 
institutional experience, though examined wide ranges of eligibility for 
anticoagulation in our analyses. 
Treatment Complications 
We derived the probability of both major fatal (0.5%) and non-fatal bleeding 
(1.1 %) due to LMWH from a meta-analysis of 11 randomized trials that examined 
LMWH versus unfractionated heparin for the treatment of acute DVT 10• 
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Thrombosis of the femoral vein or inferior vena cava is one of the most common 
serious adverse effects of IVC filter placement 27 and was the sole major 
complication considered in our modeL The 6% probability of this major 
complication of IVC filter placement was based on a randomized clinical trial that 
examined LMWH versus IVC filters 25• Systematic reviews of IVC filters have 
reported similar results based on data from non-randomized trials 27• 28 and their 
results were used for upper and lower limits of the sensitivity analyses. We did 
not consider complications due to heparin-induced thrombocytopenia because of 
the very low risk associated with LMWH and the infrequent occurrence of 
clinically significant complications 29. 
Because few data relevant to our population and this disease process exist, for 
most therapy-related complications we assumed additional days of ICU and 
hospital ward care that are estimates based on average lengths of stay of such 
patients with these diagnoses at our institution. Because the increase in ICU 
length of stay attributable to PE has not been evaluated to our knowledge, we 
based our estimate of 4 extra ICU days on institutional experience and analyses 
of other ICU complications including gastrointestinal bleeding (4 to 8 extra ICU 
days) 30 and ventilator-associated pneumonia (3 to 10 extra ICU days) 31 • 
Generally however, complications prolonged ICU stay by 3 to 4 days and hospital 
ward stay by 2 to 3 days. Costs related to death are based on a recent cost-
effectiveness model 7 , though are included only in sensitivity analyses because 
they bias the model toward the cost-effectiveness of ultrasound. 
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Costs 
The costs used in our model are shown in Table 2.Total costs of each scenario 
tested are also shown in Appendix 2. We incorporated a health care payer 
perspective and included direct medical costs. Indirect costs such as days lost 
from work by the patient or family members were not included in analyses. All 
non-pharmaceutical medical costs were standardized to 2001 US dollars by 
using the medical care component of the Consumer Price Index 32 • 
Costs of Initial Diagnosis and Treatment 
In our calculations of the inpatient costs for those critically ill patients who 
underwent ultrasound after removal of a femoral CVC, we utilized costs for 
hospital care, diagnosis and treatment of DVT, as well as costs of potential 
complications related to therapy for DVT or PE. We used the average institutional 
costs per day of care for medical ICU patients in our baseline cost calculations. 
These costs were calculated by multiplying average costs of all medical ICU 
patients treated at UNC hospitals during ihe year 2001 by the institutional cost to 
charge ratio (0.601) (Greco P, personal communication). These average charges 
include hospital costs, physician fees, average costs of laboratory tests, 
administrative costs, and electricity. Likewise, hospital ward costs in our analyses 
reflect similar institutional costs. Pharmaceutical costs were based on average 
wholesale prices for 2001 33• The costs of procedures included in our decision 
model such as ultrasound, IVC filters, esophagogastroduodenoscopy (EGO), and 
ventilation-perfusion (V/Q) scans included physician interpretation. We derived 
these costs from the so'h percentile of usual customary physician reimbursement 
rates 34 based on current procedural terminology (CPT) codes 35• Our sensitivity 
analyses for all procedural and testing costs included a lower bound of Medicare 
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Fee Scale reimbursement 34 and the upper bound the 90'" percentile of usual 
customary reimbursement. 
Costs of Complications 
Major complications of both LMWH treatment and IVC filter placement were 
considered in our analyses. For costs associated with major non-fatal bleeding 
secondary to use of LMWH, we assumed an EGD with intervention would be 
pertormed and one unit of blood transfused, similar to past cost-effectiveness 
analyses of LMWH 36• Costs for IVC filter thrombosis include an extra ultrasound 
examination. Extra days of ICU care and hospital ward care were assumed 
based on the occurrence of complications such as PE, major bleeding 30, and 
IVC thrombosis and these costs based on institutional data. 
Base-Case Analysis 
We calculated incremental cost-effectiveness ratios (ICERs) by comparing 
ultrasound versus no ultrasound in averting PE-associated death and overall PE. 
Our best estimates of probabilities for all variables included in our decision model 
were used in the base-case analysis and the uncertainty present in variables 
assessed in one- and two-way sensitivity analyses. We used DATA 4.0 (TreeAge 
Software, Williamstown, MA) and Excel (Microsoft Corporation, Redmond, WA) 
software for analyses. 
Sensitivity Analyses 
Published data have provided wide ranges of probabilities and outcomes of CVC-
associated DVT and PE. Therefore, we pertormed one-way sensitivity analyses 
by varying values of uncertain probabilities or costs within specified ranges 
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included in the decision model to investigate the effect of such differences on 
incremental cost-effectiveness ratios. In these sensitivity analyses, we 
incorporated either the greatest variability seen in medical literature, 95% 
confidence intervals of meta-analyses, or added or subtracted half of probabilities 
or costs. We also examined the probable costs associated with the worst case 
scenario in which variables were all set to minimize the positive impact of 
ultrasound. 
Two-way sensitivity analyses were also performed to examine the effect of 
changing two of the most important variables in our analysis simultaneously, 
sensitivity (as well as specificity) of ultrasound and prevalence of CVC-
associated DVT. This was done to address the presence of ultrasound operator 
differences between centers may affect overall outcomes. We also examined the 
effect of varying probability of PE associated with CVC use and probability of PE-
associated death, both variables associated with wide ranges of values in 
published literature. 
RESULTS 
Base-Case Analysis 
In the base-case analysis, performing screening ultrasound compared with no 
imaging after femoral CVC removal resulted in an increase in overall costs from 
$30,372 to $30,677 (Table 3). The incremental cost-effectiveness ratio, reflecting 
costs per PE death averted by ultrasound screening followed by appropriate 
therapy, was $14,350. In secondary analyses, use of ultrasound raised overall 
costs frorn $30,092 to $30,199 and was associated with incremental costs of 
$1 ,969 per CVC-related PE averted. 
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Sensitivity Analyses 
Results of one-way sensitivity analyses comparing ultrasound versus no 
ultrasound are shown in Figure 2. We varied the values of probabilities and costs 
that were uncertain or of perceived interest those caring for the critically ill. 
Overall, incremental cost-effectiveness ratios remained less than $50,000 per PE 
t-
death averted for most analyses, with the exception of probability of DVT and ' F 
probability of PE death. 
Costs per PE death averted became significantly greater as we increased either 
the sensitivity or specificity of ultrasound. For example, varying sensitivity from 
15% to 75% changed incremental cost-effectiveness ratios from initial cost 
savings to $17,082 per PE death averted. However, even at a sensitivity of 95%, I ultrasound cost $20,134 per PE death averted. Likewise, as specificity increased 
from 75% to 98%, cost savings dominated up to a specificity of 86% after which 
the ICER was $26,734. In two-way sensitivity analyses, we explored the effect of 
ultrasound accuracy on ICERs further by simultaneously varying sensitivity and 
specificity of ultrasound with the probability of PE (Figures 3 and 4). As both 
sensitivity and specificity were improved, the incremental costs associated with 
ultrasound in averting PE death increased. The trend toward increased costs with 
improved accuracy of imaging represents the reduction in expenses associated 
with treating ore expensive complications such as PE after '1alse negative" tests 
and major bleeding events caused by anticoagulation given for '1alse positive" 
tests. 
The effect of varying costs of ICU and hospital ward care produced wide ranging 
changes in ICERs for ultrasound screening. At $1,332 per day of ICU care, 
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preventing each PE death cost nearly $26,000. Not until daily costs of leU care 
reached $4,000 did the ultrasound strategy dominate. Similarly, doubling and 
halving ward costs changed leERs by a nearly identical factor, with lower ward 
costs associated with higher leERs. 
When we varied the prevalence of femoral eve-associated DVT from 9% to 
38%, a strategy of ultrasound screening ranged from costs of $63,805 per PE 
death averted at a prevalence of 9% to cost savings at a prevalence of 30%. 
Further, a greater incremental effect on PE death was observed at a prevalence 
of 29%, with 3 deaths averted per 100 femoral eve DVTs. An exception to the 
generally stable incremental cost-effectiveness ratios was variance of PE. When 
the probability of developing PE from a eve-associated DVT was changed, 
leERs ranged from $151,703 at a 10% probability to cost savings at 38% 
probability. When we examined probability of receiving LMWH without 
contraindications, the cost per PE prevented dropped from $22,136 at 25% to 
$12,681 at 75% likelihood, consistent with an overall cost savings of LMWH 
compared with IVC filter placement. 
Varying the costs of treatments produced a wide range of leERs. For example, 
when LMWH was available for $410, the leER was $5,031. However, when 
pharmacy costs increased to $1640, incremental costs rose to nearly $33,000 
per PE death averted. Similarly, varying IVe filter placement costs in our model 
from $600 to $2175 changed increased the leER from $6,300 to $27,503. 
Varying costs of most procedures and treatments such as ultrasound, V/Q scans, 
IVe filters, and Uv1WH had little effect, typically changing leERs less than $1 ,000 
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from the base-case scenario per PE death averted. However, varying 
probabilities of treatment-related death of both IVe filters and LMWH each 
increased leERs nearly $5,000 from that of the base-case scenario. 
~-
In analyses evaluating the cost-effectiveness of ultrasound in averting overall PE, 
varying the probability of PE with DVT was associated with costs of $60,614 per 
PE averted at a probability of 9% to cost savings at probability of PE of 32%. 
Likewise, prevalence of DVT varied leERs from $17,222 at 9% to cost savings at 
24%. 
DISCUSSION 
The critically ill have an especially high incidence of DVT, likely as a result of 
prolonged immobility, overall illness severity, and coagulation dysfunction 37• The 
optimal strategy for the prevention, detection, and treatment of central venous 
catheter-associated DVT and PE among the critically ill is unclear. We used 
decision analysis modeling based on the probabilities most relevant to the 
critically ill to examine the cost-effectiveness of performing ultrasound after 
removing femoral eves in averting PE and death attributable to PE. Our results 
suggest that an ultrasound-based screening strategy is associated with 
acceptable potential costs of $14,350 per PE death averted and $1 ,969 per PE 1 
averted. In the base-case analysis, we found that for every 100 ultrasound tests 
performed, 5 non-fatal and 2 fatal PEs could be potentially averted by using 
ultrasound screening. Our results were stable over the wide range of 
probabilities, treatment strategies, and treatment costs we examined in the 
decision modeL 
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Barriers in Decision Making 
Decision-making regarding eve-associated DVT and PE management may be 
challenging for physicians who manage critically ill medical patients. First, there 
are few data on venous thromboembolic disease specific to this population. 
Perhaps as a result, DVT and PE issues relevant to the critically ill have not been 
specifically addressed in recent statements by consensus groups such as the 
American Thoracic Society 38 and the American College of Chest Physicians 39• 
Also, the diagnosis of DVT and PE is difficult among ICU populations. Physical 
examination is inaccurate for detecting DVT among these patients 8, who 
themselves are usually unable to complain of symptoms associated with DVT 
because they are intubated and sedated. Diagnosing PE among patients who 
require mechanical ventilation is daunting, considering how commonly potential 
confounding pathophysiology is present such as pulmonary edema, pneumonia, 
and the acute respiratory distress syndrome. Although ultrasound testing 
improves diagnostic accuracy, its sensitivity and specificity is lower among the 
asymptomatic population relative to symptomatic outpatients . Nevertheless, 
ultrasound is the most common test intensivists currently use to detect DVT 
because the reference standard, contrast venography, is invasive, requires 
patient transport to an imaging department, and is perceived as having a high 
risk of nephrotoxicity. Our findings suggest that ultrasound may improve 
outcomes at an acceptable cost per PE and PE death averted with either 
anticoagulation or IVC interruption, supporting physicians' current practice. 
The Potential Value of Ultrasound Screening 
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Not all DVTs and PEs are clinically important or require immediate 
anticoagulation among the critically ill. However, considering that PE mortality is 
strongly associated with hemodynamic status 40, the attributable morbidity and 
mortality of PE within an leU population is likely to have been underappreciated. 
For those who develop PE from DVT and survive, pathophysiologic impairments 
may included increased work of breathing, increased dead space ventilation with 
resultant hypercapnea and hypoxemia, and right ventricular overload 41 • These 
changes are likely to reduce weaning success and increase days of mechanical 
ventilation. Increased time of mechanical ventilation is directly associated with 
increased complications and costs 42• 
The Potential Problems of Ultrasound Screening 
Despite the potential benefits of ultrasound, there are many possible problems 
with an ultrasound-based screening program. First, there is the concern for 
bleeding related to heparin. However, even when we increased the probability of 
major bleeding as high as 10%, over four times greater than that reported in a 
recent clinical trial of LMWH for acute PE 43 , the cost per PE death averted 
remained less than $50,000. Recognizing that many leU patients have bleeding 
diastheses, we found that if as many as 75% of patients with DVT received the 
more expensive IVe filter for treatment rather than anticoagulation, costs 
remained less than $23,000 per PE death averted. There are also overriding 
questions of femoral catheter safety relative to upper extremity eves. Although 
subclavian placement of eves was associated with nearly ten times fewer 
thrombotic complications than femoral catheters in a recent large randomized 
trial 2 , other studies have reported vessel thrombosis in up to 4 7% of subclavian 
and internal jugular vein catheters and PE in over 36% of these patients 44• 
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Therefore, choosing a site other than the femoral vein for eve placement will not 
avoid thrombotic complications completely. Finally, the role of heparin flushes in 
eves is important. Although the addition of daily heparin to eves reduce vessel 
thromboses, rates of catheter-associated venous thrombosis are still troubling 45• 
We believe that an ultrasound-based screening program of DVT detection and 
treatment could address these concerns. 
The Decision Model 
The decision model used in our analyses has particular usefulness in addressing 
eve-associated DVT and PE. First, the model accommodates individual 
assessment of probabilties and institutional differences in costs in the 
interpretation of ultrasound's cost-electiveness. This improves the generalizability I j 
f 
of our results. Our model is also able to compare the performance and costs 
associated with two different therapies for eve-associated DVT, LMWH and IVe 
filters, among the critically ill. Lastly, precisely because there is little data 
applicable to the target patient population and relevant clinical trials have been 
so difficult to perform, our model can help inform decision making by gathering 
many of the best relevant estimates of disease probability, treatment benefits and 
complications, and costs from methodologically strong clinical trials. 
The probabilities used in our model were the best estimates available relevant to 
our target population. However, some of the probability estimates we used in our 
model are likely to be controvesial. For example, both the incidence of PE 
associated with eves and the attributable mortality of these PEs is unknown. 
Our analyses instead used PE data gathered from patients with DVT 
unassociated with eves. Although it seems unlikely that PE incidence would be 
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any lower among those with eves, this is still conceivable. However, our 
sensitivity analyses showed that costs per PE death averted do not exceed 
traditional cost-effectiveness threshold values of $20,000 and $50,000 until PE 
incidence drops below relatively conservative estimates of 27% and 20%, 
respectively. Also, the probability of eve-associated DVT is not well-established 
in clinical trials that have used a reference standard. Our estimate of 21.5% is 
based on a large, methodologically strong randomized trial that used ultrasound 
as the diagnostic standard for eve-associated DVT 2 • However, this estimate is 
likely an underestimate of the true prevalence of eve-associated DVT because 
of the low sensitivity of ultrasound among the critically ill (ref) and asymptomatic 
patients 11 • 
In sensitivity analyses, we were able to address concerns of physicians regarding 
not only the potential benefits of ultrasound, but the possible adverse effects of 
treatment based on ultrasound. We found that even when the incidence of major 
bleeding related to LMWH was multiplied by a factor of four (to 1 0%), the cost 
per PE death averted remained under $50,000. Likewise, increasing the IVe filter 
thrombosis rate to 20% resulted in a cost increase to $24,555 per PE death 
prevented. Because of higher cost of IVe filter placement and greater risk of 
complications, LMWH therapy was associated with lower incremental costs. 
However, institutional and operator-dependent differences may be important 
when considering interventions. Overall, incremental cost-effectiveness ratios 
remained less that $30,000 per PE death averted over the full ranges of 
probabilities and costs examined, yet were sensitive to small changes from base-
case values. 
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The daily costs of leU and hospital ward care had a smaller effect than disease 
probabilities on incremental cost-effectiveness ratios in our analyses. There are 
many likely reasons why this was observed. First, because severity of illness and 
length of stay was not considered in these data, the true costs of PE are likely 
underestimated, because patients who require mechanical ventilation have 
average leU and hospital stays that are significantly longer than those who do 
not need respiratory support 46 . Also, we have attempted to use conservative 
cost estimates in our model in order to reduce potential bias in favor of 
ultrasound. Further, we have not included costs of death in our model, unlike 
some recent cost-effectiveness analyses 7 , which would bias our analyses 
against "standard of care". 
The Course for Future Research 
Our decision model is helpful in highlighting areas where more research is 
needed to clarify the burden of venous thromboembolic disease among the 
millions of leU patients who receive eves annually. Epidemiologic data are 
needed on incidence of eve-associated DVT and PE. Further, imaging tests 
need to be rigorously tested in this complicated population versus reference 
standards of pulmonary angiography and contrast venography to better assess 
their value relative to the same tests performed among symptomatic, non-
critically ill populations. The fact remains that physicians caring for leU patients 
currently use tests to detect PE and DVT that have uncertain accuracy within this 
population, including helical computerized tomography (eT) and ultrasound. 
Also, the value of rapid assays for thrombosis such as D-dimer may provide 
benefit to patients when their role is better defined. Finally, it is important to 
better appreciate factors associated with vessel thrombosis such as relationship 
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to time left in situ, affect of underlying disease process (sepsis, cancer), heparin 
flushing dose and flushing frequency, and type of infusate (TPN versus other). 
Overall, more research is needed to describe the attributable morbidity, mortality, 
and costs of venous thromboembolic disease among the critically ill. 
Limitations 
It is important to consider the limitations of our model and analyses. First, few 
data exist on the incidence of PE and PE mortality specific to the critically ill. 
However, it is likely that such data may not become available soon for both 
ethical and logistical reasons because many physicians may be reluctant to 
enroll their severely ill patients in clinical trials examining PE incidence and 
treatment because of concerns for contrast-induced nephrotoxicity associated 
with angiography and venography, the reference standards for PE and DVT 
diagnoses. Further, other diagnostic imaging modalities including helical 
computerized tomography (eT) and V/Q scans, require transport of patients to 
other areas of the hospital which might place patients at increased risk for 
adverse outcomes and require additional staffing. Likewise, the true accuracy of 
ultrasound pertormed on medical leU patients is unknown. However, our 
sensitivity analyses accounted for potentially wide variability in both PE incidence 
and ultrasound sensitivity and specificity. 
We used the some of the most methodologically strong data available for 
probabilities and costs in our model. Nevertheless, our model may underestimate 
the true impact of eve-associated DVT and PE. First, we did not incorporate the 
morbidity and mortality of eRBI, which has mortality rates ranging from 10-25% 
and increases hospital costs significantly 47 • Such catheter-associated 
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thrombosis is strongly related to eRBI among the critically ill 22• Also, mortality 
attributable to PE among the critically ill is not known. Although we used rates 
gathered from non-critically ill patients, it is probable that these too are 
underestimates because of the association between hemodynamic status and 
PE mortality . Also, we did not include costs associated with death, which would 
have further biased the model toward ultrasound. 
Conclusion 
A good screening test is accurate, relatively inexpensive, and can improve 
outcomes of an otherwise serious disease 48• Although we have shown that 
ultrasound screening may prevent potentially fatal PEs at acceptable costs to the 
health care payer over a wide range of disease probabilties and costs of 
treatment, it is premature to recommend routine ultrasound-based screening and 
treatment of eve-associated DVT in the absence of relevant clinical trials. First, 
the true attributable morbidity and mortality of DVT and PE must be determined 
among those who are at greatest risk for poor outcomes-the critically ill. 
However, in the absence of such definitive data, the potential burden of disease 
associated with catheter-related DVT and PE among the critically ill is sobering: 
even at a 10% prevalence of DVT, a 10% incidence of PE associated with DVT, 
and a 10% probability of death from untreated PE, a group of 1000 critically ill 
patients with femoral eves will experience 10 PEs and 1 PE-related death. 
When multiplied by the millions who receive femoral eves annually, it becomes 
apparent that there is likely room for improved outcomes from venous 
thromboembolic disease among the critically ill. 
24 
L 
'-1 
1 
1= 
r 
' ' I 
r 
I 
I 
l 
CoxCE 
We have shown that screening ultrasound versus no ultrasound performed after 
removal of femoral eves may be cost-effective in preventing both PE-associated 
death and overall PE. This is the first cost-effectiveness study of screening 
ultrasound to prevent CVC-associated PE, to our knowledge. In the absence of 
randomized clinical trials examining detection and prevention of eve-associated 
PE within the critically ill population, physicians should consider performing 
screening ultrasound tests after removing femoral vein CVCs. The potentially 
large burden of venous thromboembolic disease among the critically ill warrants 
further study in areas of epidemiology, prevention, detection, and treatment. The 
clinical outcomes of critically ill patients may be improved significantly through a 
better understanding of DVT and PE. 
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Table 1: Probability estimates lor base-case scenario and ranges lor sensitivity analyses 
Base-Case 
Variable Value (Range) Reference 
Femoral eve-associated DVT 21.5 (9,38) 2,15-22 
Sensitivity of ultrasound 62 (15-75) 11, 49 
Specificity of ultrasound 94 (75-98) 11,49 
DVT -associated PE 30 (1 0-51) 2, 3, 5, 23, 50 
PE while on LMWH 1.9 24 
PE death with LMWH 0.5 10 
PE death without LMWH/IVe 30 (18-38) 26 
PE alter IVe filter placement 1.1 25 
No contraindications to LMWH 66 (25-75) Estimate 
Major LMWH-related bleeding 1.1 (1-5) 10,43 
Death from LMWH-related bleeding 0.5 (0.1-2.5) 10,43 
IVe thrombosis due to 6 (4-11) 25, 27,28 
IVe filter placement 
27 Death due to filter complications 0.12 (.06-1) 
--"w'''~'' ··~·w-o• ~ '·"~"'•""·" '""''"'''""'"~'''"""""'"'"'''*"'''"'~-«•"'"'""~"'~"'~'"''~-,.,"~''"'4''"""'""'"'''""~'""-""''""''~ ''"'"""~''""''~"'~~•""''~IT!f'l''"''"'"-" '""''"'' "''""'"""·'"''~'"' ""'""l'\llfUIIIR'f'tfll'~"l'"~'"·'~'""'~"""~'1'tfFtr"""""4~''&"" '""'"'"' '""""~="'''""'!'!' """"r",_,~,, ''"1''"'' ., .. ,,~ ·····rn---·~·rr•nmtll'lll'~n-·1·" 
Base-Case 
Value,$ (Range)' Reference 
Costs of initial hospitalization 
Ultrasound with interpretation 235 (151-389) 34,35 
LMWH for 10 day course 820 (410-1640) 33 
ICU costs for 8 days 19,7'12 (9,856-39,424) Institutional 
Hospital ward costs for 7 days 9,410 ( 4,705-18,820) Institutional 
IVC filter placement 1,198 (600-2175) 34,35 
Costs of major complications 
Additional ICU day 2462 (1231-4924) Institutional 
Additional ward day 1343 (671-2686) Institutional 
Major bleeding episode 8626 (4193-16,780) 34-36 :j: 
V /Q scan w/ interpretation 342 (133-541) 34,35 
Major IVC filter complication 5383 (2, 724-1 0,685) 34,35 t 
' Death from any cause 2500 (0-5000) 12 
·1n 2001 US dollars 
t Assumes procedure-related DVT or lVC thrombosis. Includes two extra days of ICU care, repeat ultrasound 
:t:Major bleeding included EGO w/ intervention, 3 extra ICU days30, 2 extra ward days, and transfusion of 1 unit of blood 
Table 2: Costs and cost-related data incorporated in the decision model 
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Overall Incremental 
--
Scenario Strategy Cost($) Effect Cost ($) Effect C/E Ratio 
PE Death Averted no ultrasound 30,084 0.98 
ultrasound 30,351 1.00 267 0.02 14,350 
PE Averted no ultrasound 30,092 0.94 
ultrasound 30,199 0.99 107 0.05 1,969 
Table 3: Results of Cost-Effectiveness Analysis Comparing Screening Ultrasound Versus 
No Ultrasound in Preventing Femoral CVC-Associated Complications-Base-Case Scenario 
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Figure 1: Decision tree model for ultrasound detection of femoral eve-associated DVT 
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Figure 2: Results of one-way sensitivity analyses. The range of values examined is depicted on either side of each bar. Incremental cost 
effectiveness ratios less than $0 indicate cost-savings; those greater than zero indicate additional costs of ultrasound screening. 
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Figure 3: Two-way sensitivity analysis of probability of DVT and sensitivity of 
ultrasound. Incremental cost-effectiveness ratios are labelled with costs per 
PE death averted. 
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Figure 4: Two-way sensitivity analysis of probability of DVT and specificity of 
ultrasound. Incremental cost-effectiveness ratios are shown. Incremental 
cost-effectiveness ratios are labelled with costs per PE death averted. 
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Appendix 1: Systematic Review of Femoral eve-Associated DVT 
Literature Search Strategy 
We systematically searched MEDLINE between January 1966 and March 2002 
as well as the Cochrane Collaboration Database of Systematic Reviews and the 
Database of Abstracts of Reviews for relevant manuscripts and abstracts. The 
following medical subject heading (MeSH) and text words were used to search 
for potentially relevant articles: ''femoral vein", "venous thrombosis", 
"thromboembolism", "central venous catheterization", "peripheral venous 
catheterization", "central line", and "deep vein thrombosis". We then cross-
referenced this search with a second that included "intensive care units", "critical 
care", "critical illness", and "intensive care". Only articles written in English and 
that included adult patients were reviewed for this analysis. 
Selection of Articles for Inclusion 
The computer-based literature search was done by the primary author (C.C.). 
Articles were included in the systematic review if they fulfilled the following 
criteria: 
• randomized controlled or prospective cohort study design 
• severely ill adult patients admitted to medical or surgical intensive care units 
• femoral venous catheters used; and 
• an objective imaging test was used to verify the presence of DVT such as 
venous ultrasound, impedance plethysmography, fibrinogen scan, or 
venography 
We excluded studies that did not focus primarily on eve-associated 
complications or did not specify relation of thrombosis to catheter location 
(femoral, subclavian, or internal jugular). 
Outcome Definitions 
Catheter-associated DVT was defined as partial or complete thrombosis of the 
proximal femoral vein on the ipsilateral side to a femoral eve, demonstrated by 
an imaging test. 
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Data Extraction 
The primary author abstracted data from each relevant article on study design, 
patient characteristics, enrollment strategy (consecutive versus not), type of 
imaging study performed, use of venography as a comparative gold standard 
when ultrasound performed, frequency of DVT associated with catheter use, 
location of catheter, duration of catheter use, blinding of outcomes assessment, 
and completeness of follow-up. Because few randomized trials exist that are 
relevant to this issue among the critically ill, we did not use an established validity 
scale to rate the strength of study results. Instead, we included all prospective 
studies, cohort or randomized, that used an imaging test to evaluate DVT in 
patients with femoral eves. 
Statistical Methods 
The incidence of femoral eve-associated catheterization was evaluated using 
odds ratios (ORs) and 95% confidence intervals (Cis) calculated for each study. 
Summary ORs were calculated using Mantei-Haenszel methods under a 
random-effects model. We examined a funnel plot of standard errors to 
determine existence of evidence for publication bias. The Q statistic was 
calculated to test for significant heterogeneity among studies. Analyses were 
done including all studies (including prospective studies using the contralateral 
femoral vein as a control) as well as for only the 3 randomized controlled trials. 
We used Comprehensive Meta-Analysis software (Biostat, Englewood NJ) for 
our analyses. 
Results 
Study Selection 
A total of 232 articles were located from all sources using our search terms. 
Many articles were case reports, addressed hemodialysis catheters, or focused 
on oncology patients. We identified four prospective studies 16.19 and three 
randomized clinical trials 2· 21 • 51 that mei criteria for inclusion in the systematic 
review. A summary of the eight studies is given in Appendix Table 1. 
36 
l 
L 
t 
i 
I 
I 
t 
L 
~ 
' ! I 
I 
r 
i 
' 
CoxCE 
Study, Patient Imaging Catheter Total Total 
year Design Population Test Duration,d (sd) Catheters DVT 
Meredith, Cohort Trauma Duplex U/S 76 9 
1993 76 2 (cFV) 
Mian, Cohort Hospitalized Duplex U/S 42 11 
1997 42 0 (cFV) 
Durbec, Cohort MICU/SICU Venography 8.8 (4.4) 70 6 
1997 
Joynt, Cohort MICU/SICU Compr+Duplex 4 (2) 124 12 
2000 5 (3) 124 2 (cFV) 
Trottier, RCT MICU/SICU Duplex U/S 3.8 (1.5) 24 6 
1995 4.2 (2.4) 21 0 (SCL) 
Durbec, RCT MICU/SICU Venography 7.1 (4.6) 31 3 
1997 9.9 (5.5) 30 1 (IJ) 
Merrer, RCT MICU Doppler U/S 9.6 (6.3) 116 25 
2001 11.3 (6.4) 107 2 (SCL) 
Appendix Table 1: Studies reviewed for systematic review of eve-associated 
venous thrombosis. ReT =randomized controlled trial, MleU=medical intensive care 
unit, SleU=surgical intensivie care unit, U/S=ultrasound, cFV=contralateral femoral 
vein, IJ=internal jugular vein, SeL=subclavian vein 
Studies included a total of 641 patients with 483 femoral catheters. Most patients' 
catheters were triple-lumen and the mean duration of femoral eve use ranged 
from 3.8 to 9.6 days. Most patients were enrolled from medical or surgical JeUs. 
The primary imaging modality was duplex ultrasound and only two studies used 
the reference standard of venography 19• 51 • Most patients in these studies were 
receiving some type of DVT prophylaxis in the form of heparin or sequential 
compression devices. 
Overall, femoral eves were associated with a greater risk of venous thrombosis 
compared to contralateral femoral vein controls or upper extremity eves (OR 
8.55, 95% e;, 4.1, 17.9). When only randomized trials were included in the 
analysis, the association between femoral eve use and venous thrombosis was 
even greater than upper extremity eves (OR 10.0, 95% eJ, 3.2, 31.4). There 
was not significant heterogeneity (0=2.94, p=0.82). All ORs are shown in 
Appendix Table 3 and a Forrest plot of study results in Appendix Figure 1. 
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Venous Thromboses, no. (%) 
Study, y Treatment Control OR (95% Cl) 
Meredith, 9(11.8) 2 (2.6) 5.0 (1.0, 23.8) 
1993 
Mian, 11 (26.2) 0 (0) 31.0 (1.8, 546.6) 
1997 
Durbec, 6 (8.6) n/a 14.2 (0.8, 257.3) 
1997 
Joynt, 12 (9.7) 2 (1.6) 6.5 (1.4, 29.9) 
2000 
Trottier, 6 (25.0) 0 (0) 15.1 (0.8, 286.6) 
1995 
Durbec, 3 (9.7) 1 (3.3) 3.1 (0.3, 31.7) 
1997 
Merrer, 25 (21.6) 2 (1.9) 14.4 (3.3, 62.6) 
2001 
Appendix Table 3: Odds ratios for eve-associated venous thrombosis 
Systematic Review 
Citation Year Effect Lower Upper PValue 0.1 0.2 0.5 
durbec 1 199714.209 
durbec 2 1997 3.107 
joynt 2000 6.536 
meredith 1993 4.970 
merrer 200114.423 
mian 199731.032 
trott!er 199515.108 
RandomCombined (7) 8.554 
.785!57.262 
.305 31.680 
1.431 29.846 
1.037 23.828 
3.325 62.565 
1.762546.583 
.796286.592 
4.098 17.854 
.020 
.317 
.006 
.028 
.000 
.001 
.023 
.000 
Control/Upper Extremity 
2 
Femoral 
CoxCE 
5 10 
Appendix Figure 1: Odds ratios and Forrest plot of venous thrombosis associated with 
both upper extremity and femoral vein eves 
Most trials enrolled small numbers of patients and did not use the reference 
standard, venography, to confirm the presence of venous thrombosis. However, 
considering that the sensitivity and specificity of ultrasound for detecting proximal 
DVT among post-operative orthopedic patients (a group with similarities to 
medical ICU patients) was found to be 75% and 98%, respectively, this suggests 
that femoral DVT may have been underdiagnosed rather than overdiagnosed in 
these studies. It is therefore possible that the true increased odds of DVT may 
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approach the upper bound of the 95% confidence intervals found in these 
studies. 
Conclusion 
Femoral central venous catheters are associated with an increased odds of 
venous thrombosis relative to upper extremity catheters or "control" femoral 
veins. The most methodologically rigorous study examined demonstrated the 
largest OR of 14.4 (95% Cis 3.3, 62.6). Femoral CVCs should be used sparingly 
among the critically ill when proximal DVT-associated complications are a 
concern. 
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Appendix 1: Total costs and cost-related data incorporated in the decision model by clinical scenario 
Base-Case Value, 
Scenario $(Range) Reference 
DVT/LMWH/no complications 30,177 (15, 122-60,273) 
34
' 
35
, CPT code 93971 Ultrasound with interpretation 235 (151-389) 
LMWH (10 days) 820 (410-1640 33 
ICU costs 19,712 (9,856-39,424) Institutional; 8 days 
Hospital ward costs 9,41 0 (4, 705-18,820) Institutional; 7 days 
DVT/LMWH/major bleeding 41,203 (20,546-81 ,963) 
33 LMWH 820 (410-1,640) 
Ultrasound with interpretation 235 (151-389) 34' 35, CPT code 93971 
ICU costs 27,104 (13,552-54,208) Institutional; 11 days 
Hospital ward costs 12,087 (6,044-24, 174) Institutional; 9 days 
Transfusion 150 (75-300) Institutional 
EGD/MD fees 807 (314-1 ,252) 34' 35, CPT code 43227 
DVT/LMWH/PE 44,395 (22, 193-88,566) 
Ultrasound with interpretation 235 (151-389) 34' 35 , CPT code 93971 
LMWH 820 (410-1,640) 33 
ICU costs 29,568 (14,784-59, 136) Institutional; 12 days 
Hospital ward costs 13,430 (6,715-26,860) Institutional; 10 days 
V/Q scan w/ interpretation 342 (133-541) 34' 35, CPT code 78588 
DVT/IVC Filter/no complications 30,555 (15,312-60,808) 
34
' 
35
, CPT code 93971 Ultrasound with interpretation 235 (151-389) 
ICU costs 19,712 (9856-39,424) Institutional; 8 days 
Hospital ward costs 9,410 (4,705-18,820) Institutional; 7 days 
IVC filter placement 1 '198 (600-2, 175) 34' 35 , CPT code 75940 
:t::t: Assumes procedure~related DVT or JVC thrombosis. Includes two extra days of ICU care, repeat ultrasound, lab testing, and extra physician visit 
tlncludes a ventilation-perfusion scan, two extra ICU days, and two extra hospital days . 
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Appendix 1 (continued): Total costs and cost-related data incorporated in the decision model by clinical scenario 
Base-Case Value, 
Scenario $(Range) Reference 
DVT/IVC filter/complications 35,931 (18,034-71,479) 
Ultrasound with interpretation 235 (151-389) 34' 35, CPT code 93971 
ICU costs 22,176 11 ,088-44,352) Institutional; 9 days 
Hospital ward costs 12,087 (6,044-24,174) Institutional; 9 days 
IVC filter placement 1 '198 (600-2, 175) 34' 35, CPT code 75940 
Repeat ultrasound 235 (151-389) 34' 35, CPT code 93971 
DVT/IVC filter/PE 44,773 (22,383-89,101) 
Ultrasound with interpretation 235 (151-389) 34' 35, CPT code 93971 
IVC filter placement 1 '198 (600-2, 175) 34' 35, CPT code 75940 
ICU costs 29,568 (14,784-59, 136) Institutional; 12 days 
Hospital ward costs 13,430 (6,715-26,860) Institutional; 10 days 
V/Q scan w/ interpretation 342 (133-541) 34' 35, CPT code 78588 
False negative test/DVT/no PE 29,357 (14, 712-58,633) 
34
' 
35
, CPT code 93971 Ultrasound with interpretation 235 (151-389) 
ICU costs 19,712 (9,856-39,424) Institutional; 8 days 
Hospital ward costs 9,410 (4,705-18,820) Institutional; 7 days 
False negative test/DVT/PE 44,395 (22,193-88,566) 
34
' 
35
, CPT code 93971 Ultrasound with interpretation 235 (151-389) 
LMWH therapy 820 (410-1,640) 33 
ICU costs 29,568 (14,784-59,136) Institutional; 12 days 
Hospital ward costs 13,430 (6,715-26,860) Institutional; 10 days 
V/Q scan w/ interpretation 342 (133-541) 34' 35 , CPT code 78588 
No test/DVT/no initial therapy/PE 44,160 (22,042-88,177) 
33 LMWH therapy 820 (410-1 ,640) 
ICU costs 29,568 (14,784-59,136) Institutional; 12 days 
Hospital ward costs 13,430 (6,715-26,860) Institutional; 10 days 
V/Q scan w/ interpretation 342 (133-541) 34' 35, CPT code 78588 
++Assumes procedure-related DVT or IVC thrombosis. Includes two extra days of ICU care, repeat ultrasound, lab testing, and extra physician visit 
tlncludes a ventilation-perfusion scan, two extra ICU days, and two extra hospital days. 
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